NRx Pharmaceuticals to Report Q2 2025 Financial Results on August 14, 2025

NRx Pharmaceuticals will report Q2 2025 financial results on August 14, 2025. The company will provide a corporate and financial update, focusing on recent regulatory events, strategy, and operational plans. A conference call will be held at 4:30pm ET, and a live webcast will be available on the company's website. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will release its second-quarter 2025 financial results after the market closes on August 14, 2025. The company will provide a comprehensive update, focusing on recent regulatory events, strategic direction, and operational plans. A conference call is scheduled for 4:30 PM ET, and a live webcast will be available on the company's website [1].

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders. The company's pipeline includes NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of suicidal ideation in Depression, including Bipolar Depression, while NRX-101 has been granted Breakthrough Therapy Designation for the treatment of suicidal bipolar depression [2].

The company recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application (NDA) filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement [2].

Investors are advised to closely monitor the company's earnings report and the subsequent conference call for insights into the company's financial performance, regulatory progress, and strategic initiatives.

References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3131244/0/en/NRx-Pharmaceuticals-Inc-NASDAQ-NRXP-to-Report-Second-Quarter-2025-Financial-Results-on-August-14-2025.html
[2] https://www.nasdaq.com/articles/3-biotech-stocks-likely-outpace-q2-earnings-estimates